548 related articles for article (PubMed ID: 18084743)
1. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
West R; Baker CL; Cappelleri JC; Bushmakin AG
Psychopharmacology (Berl); 2008 Apr; 197(3):371-7. PubMed ID: 18084743
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
[TBL] [Abstract][Full Text] [Related]
3. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Gonzales D; Jorenby DE; Brandon TH; Arteaga C; Lee TC
Addiction; 2010 Nov; 105(11):2002-13. PubMed ID: 20819082
[TBL] [Abstract][Full Text] [Related]
5. Varenicline: a first-line treatment option for smoking cessation.
Garrison GD; Dugan SE
Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
[TBL] [Abstract][Full Text] [Related]
6. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
7. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
8. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
9. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
10. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
11. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Cinciripini PM; Robinson JD; Karam-Hage M; Minnix JA; Lam C; Versace F; Brown VL; Engelmann JM; Wetter DW
JAMA Psychiatry; 2013 May; 70(5):522-33. PubMed ID: 23536105
[TBL] [Abstract][Full Text] [Related]
12. Effects of varenicline on smoking cue–triggered neural and craving responses.
Franklin T; Wang Z; Suh JJ; Hazan R; Cruz J; Li Y; Goldman M; Detre JA; O'Brien CP; Childress AR
Arch Gen Psychiatry; 2011 May; 68(5):516-26. PubMed ID: 21199958
[TBL] [Abstract][Full Text] [Related]
13. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
King DP; Paciga S; Pickering E; Benowitz NL; Bierut LJ; Conti DV; Kaprio J; Lerman C; Park PW
Neuropsychopharmacology; 2012 Feb; 37(3):641-50. PubMed ID: 22048466
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
Bailey SR; Crew EE; Riske EC; Ammerman S; Robinson TN; Killen JD
Paediatr Drugs; 2012 Apr; 14(2):91-108. PubMed ID: 22248234
[TBL] [Abstract][Full Text] [Related]
15. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis.
Nides M; Glover ED; Reus VI; Christen AG; Make BJ; Billing CB; Williams KE
Am J Health Behav; 2008; 32(6):664-75. PubMed ID: 18442345
[TBL] [Abstract][Full Text] [Related]
16. Varenicline: for smoking cessation.
Rao J; Shankar PK
Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
[TBL] [Abstract][Full Text] [Related]
17. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
[TBL] [Abstract][Full Text] [Related]
18. Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials.
Foulds J; Russ C; Yu CR; Zou KH; Galaznik A; Franzon M; Berg A; Hughes JR
Nicotine Tob Res; 2013 Nov; 15(11):1849-57. PubMed ID: 23694782
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
[TBL] [Abstract][Full Text] [Related]
20. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2007 Jan; (1):CD006103. PubMed ID: 17253581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
